Development of new strategies of human antitumor dendritic cell vaccines

Projektinformationen

MYRTO-GEORDIA TRAKAT

ID Finanzhilfevereinbarung: QLK2-CT-1999-51390

Projekt abgeschlossen

Startdatum 1 August 2000

Enddatum 31 Juli 2002

Finanziert unter

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Gesamtkosten € 159 400,00

EU-Beitrag € 159 400,00

Koordiniert durch

UNIVERSITE LIBRE DE BRUXELLES
Belgium

Ziel

The project aims to investigate in healthy donors and in melanoma patients, strategies that could improve the generation of MAGE-specific antitumor cytotoxic immune responses by vaccination with autologous dendritic cells.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › oncology › skin cancer › melanoma
• medical and health sciences › basic medicine › immunology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines

Programm/Programme

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Thema/Themen

• 1.1.1.-2. - Key action Control of Infectious Diseases

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

RGI - Research grants (individual fellowships)

Koordinator

UNIVERSITE LIBRE DE BRUXELLES

• EU-Beitrag: Keine Daten
• Adresse: Route de Lennik 808 ; 1070 BRUXELLES ; Belgien
• Gesamtkosten: Keine Daten